Ardea Biosciences (RDEA) Gets $7.5M Milestone from Bayer for MEK Inhibitor Development

Article Stock Quotes (1) Comments (0)

Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it has earned a $7.5 million milestone from Bayer HealthCare (Bayer) under the terms of their April 2009 global license agreement to develop and commercialize Ardea's mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications. The milestone was triggered by the initiation of the Phase 2 part of a previously reported Phase 1/2 clinical study evaluating the investigational agent BAY 86-9766 in combination with gemcitabine for the treatment of advanced pancreatic cancer.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Acacia Research (ACTG) Enters Settlement with Red Hat (RHT)
• Barrick Gold (ABX) Says it is Assessing Situation in Chile
• Gleacher & Co. (GLCH) Reports Election of Five for Board Members

Create E-mail Alert Related Categories

Corporate News

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?